This 7% Yielder Could Be a Top AI Play

Key PointsA looming patent cliff in which Pfizer will lose patent exclusivity to a handful of drugs has combined with cratering revenue from COVID-19 treatments to drive Pfizer shares down 50% since 2022.

admin